Follow
Vasile Musteata
Vasile Musteata
Other namesВасилий Мустяцэ, Vasile Musteață
State University of Medicine and Pharmacy "N. Testemitanu", Institute of Oncology
Verified email at usmf.md
Title
Cited by
Cited by
Year
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
T Robak, M Kaźmierczak, I Jarque, V Musteata, J Treliński, N Cooper, ...
Blood advances 4 (17), 4136-4146, 2020
912020
Phase II, multiple-dose study of anti-FcRn antibody, rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis
T Robak, I Jarque, V Musteata, P Kiessling, U Massow, J Higginson, ...
Blood 130, 15, 2017
162017
Targeted therapy of chronic myelogenous leukemia: experience of the Institute of Oncology of Moldova
V Musteata, I Corcimaru
Archives of the Balkan Medical Union 43 (3), 154-155, 2008
142008
GIPAP īn Republica Moldova: realizări şi perspective
M Vasile, C Ion, S Mircea-Dumitru, M Larisa, R Maria, T Ludmila, C Maria, ...
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 16 (2), 226-228, 2008
122008
A phase 2 study of MT-3724 to evaluate safety, pharmacodynamics and efficacy of MT-3724 for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma
DO Persky, V Musteata, M Zodelava, T Perekhrestenko, AE Diaz, ...
Blood 134, 5324, 2019
72019
Rozanolixizumab, an anti-FcRn antibody: final results from a phase II, multiple-dose study in patients with primary immune thrombocytopenia
T Robak, M Kaźmierczak, I Jarque, V Musteata, J Trelinski, N Cooper, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
62019
Actualități īn managementul limfoamelor non-Hodgkin: profilul epidemiologic și socioeconomic
V Musteață
Общественное здоровье, экономика и менеджмент в медицине, 26-32, 2021
52021
S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY
T Robak, M Kaźmierczak, I Jarque, V Musteata, J Treliński, N Cooper, ...
HemaSphere 3, 379, 2019
52019
Treli nski
T Robak, M Kazmierczak, I Jarque, V Musteata
J, 0
5
Clinico-laboratory pertinences and management of relapsed and refractory chronic myeloid leukemia
V Musteata
Journal of BUON 26 (3), 1165-1168, 2021
32021
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse …
AE Diaz Duque, T Perekhrestenko, V Musteata, M Zodelava, TH Guthrie, ...
Journal of Clinical Oncology 38 (15_suppl), TPS8074-TPS8074, 2020
32020
Manifestările clinice şi tratamentul limfoamelor Non-Hodgkin mediastinale la adulţi
M Robu, I Corcimaru, L Musteaţă, M Popescu, V Gladīş, V Musteaţă, ...
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 48 (3), 366-371, 2015
32015
Epidemiological and Disease Burden Profiles of Leukemias and Malignant Lymphomas: Overview and Trends in the Republic of Moldova and Worldwide
V Musteata
International Journal of Clinical Medicine 14 (2), 79-95, 2023
22023
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
PA Hamlin, V Musteata, SI Park, C Burnett, K Dabovic, T Strack, ...
Cancer Research Communications 2 (5), 307-315, 2022
22022
Management of elderly patients with chronic myeloproliferative hemopathies
V Musteaţă, V Stratan, L Catrinici, L Musteaţă, C Dudnic
Moldovan Medical Journal 63 (6), 12-15, 2020
22020
Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724, in subjects with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
PA Hamlin, V Musteata, M Zodelava, SI Park, C Burnett, K Dabovic, ...
Blood 134, 4098, 2019
22019
Rezultatele utilizării target-terapiei īn tratamentul combinat al tumorilor gastrointestinale stromale (GIST)
M Cernat, N Ghidirim, I Mişin, L Antoci, A Donscaia, V Catrinici, ...
Arta Medica 60 (3), 49-49, 2016
22016
Clinical patterns and complete blood count parameters in the young patients with primary myelofibrosis in the prefibrotic stage
N Sghibneva-Bobeico, V Musteaţă, M Robu, L Jalbă, L Musteaţă, ...
Revista de Ştiinţe ale Sănătăţii din Moldova 30 (4), 22-26, 2022
12022
Epidemiology and risk factors of warm and cold autoimmune hemolytic anemia
M Vasile, TA Khan
EDITOR COORDINATOR, 225, 2021
12021
Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.
V Tomacinschii, M Robu, I Corcimaru, V Musteaţă, L Musteaţă, ...
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 59 (2-3), 61-65, 2018
12018
The system can't perform the operation now. Try again later.
Articles 1–20